Why choose the t:slim X2
The t:slim X2 is a tubed insulin pump designed for users who value both innovation and reliability. Its full-colour touchscreen, rechargeable battery, and intuitive interface make it feel more like a smartphone than a medical device.
When paired with a Dexcom CGM, Control-IQ activates a hybrid closed-loop algorithm that automatically adjusts basal rates and delivers small correction boluses throughout the day and night. The result is fewer highs and lows and less manual management.
Built for real life
The t:slim X2 is designed with real-life needs in mind, combining durability, connectivity, and user comfort:
- Slim touchscreen design: Modern, full-colour interface that is fast and intuitive
- Large insulin capacity: 300-unit cartridge for higher insulin requirements
- Rechargeable power: Lithium-polymer battery (charges about every 5–7 days)
- Watertight protection: Rated IP27 (up to 3 ft or 0.9 m for 30 minutes, not swim-proof)
- Smart connectivity: Bluetooth for CGM and smartphone integration
- Durable and discreet: Compact (112 g), designed for daily comfort
At a glance
Who can use it
The t:slim X2 with Control-IQ is approved for people who meet certain medical and age criteria.
Approved for:
- Ages 6 years and older with type 1 diabetes (Control-IQ)
- Pump alone: ages 6 and older without Control-IQ
To ensure safe and effective use, certain requirements must be met.
Requirements:
- Minimum 10 units of insulin per day
- Minimum 25 kg (55 lb) body weight
Some individuals should not use the t:slim X2 with Control-IQ due to safety or clinical reasons.
Not suitable for:
- Children under 6 years old (for Control-IQ)
- Pregnant women
- People on dialysis or who are critically ill
- Users taking hydroxyurea
Before starting, users should be comfortable with basic diabetes self-management skills.
You’ll need to:
- Check glucose as directed by your healthcare provider
- Accurately count carbohydrates
- Maintain regular follow-up visits
- Have sufficient vision or hearing to recognize pump alerts
Control-IQ automation
Control-IQ technology continuously predicts glucose trends 30 minutes ahead and adjusts insulin delivery every 5 minutes to help keep you in range. The system is designed to learn your unique needs and adapt automatically over time.
- Learns your needs: Predictive modelilng adapts to your glucose patterns
- Prevents highs and lows: Delivers auto-correction boluses (up to once per hour) and suspends insulin if a low is predicted
- Adapts to your routine: Sleep and exercise modes adjust targets
- Keeps you in control: You still enter meals and confirm boluses
Over time, it reduces decision fatigue and provides a smoother, more stable glucose experience.
Managing your data
The t:connect mobile app and Tandem Source platform make it easy to view and manage your data. Together, they give you and your healthcare team better insight into your glucose trends and insulin delivery patterns.
- View insulin, CGM, and pump data from a single dashboard
- Sync automatically to Tandem Source for cloud review
- Gain data-driven insights for you and your care team
- Software updates are done via computer connection, not over the air
What clinical studies show
Clinical and real-world studies consistently show that Control-IQ technology improves glucose control and quality of life for users.
Reported averages include:
- Around +11% time in range compared to standard pump therapy
- Fewer low and high events, especially overnight
- Improved A1C and reduced daily stress
Users commonly report greater confidence and less mental load thanks to predictive automation.
Costs and coverage in Canada
In Canada, the total cost of using the t:slim X2 depends on whether you pay out-of-pocket or through insurance or provincial coverage.
Pump hardware:
- Approx. CAD $6,300-$6,995
- Warranty: 5 years
- Annualized cost: about $1,260-$1,399 per year
Monthly supplies:
- Infusion sets (10/month): about $200-$250
- Cartridges (10/month): about $60-$80
- Estimated total: about $260-$300 per month
Coverage:
- Provincial programs: vary widely; many cover youth and young adults
- Private insurance: often 50-100% coverage under durable medical equipment (DME) Out-of-pocket: depends on plan and province
For more information on how pump coverage varies by province and territory, visit our Guide to insulin pump coverage in Canada.
Before you decide
Before choosing the t:slim X2, it’s important to understand what daily use involves. The pump recharges every five to seven days and uses a tubed design that many find reliable. Control-IQ requires a Dexcom CGM connection but continues basal delivery if the signal is lost. Coverage varies by province and insurance plan, so confirm eligibility before purchase. Users complete a short online training (about 30-45 minutes) before starting, and infusion sets are changed every two to three days for consistent insulin delivery.
Is the t:slim X2 right for you
The t:slim X2 may be a strong option for individuals who:
- Want proven automation: Control-IQ algorithm adjusts insulin every five minutes
- Use a Dexcom G6 or G7
- Prefer a rechargeable pump
- Need a large reservoir (300 units)
- Value app connectivity and cloud data sharing
How to get started
Switching to an insulin pump is a structured process that involves support from both your healthcare team and Tandem’s training program:
- Talk to your healthcare team to get a prescription and referral
- Verify coverage with your insurer or provincial program Request information at tandemdiabetes.ca or through a diabetes clinic
- Complete training through an online learning module (about 30-45 minutes)
- Start with support from your educator and Tandem’s team to optimize your settings
The typical timeline from consultation to active use is about one to three months, though it can take longer depending on funding approval, clinic scheduling, and individual circumstances. Your diabetes practitioner can provide a more accurate timeline based on your specific situation and location.
References
- Tandem Diabetes Care. (2020, November). Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology. Retrieved from https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-health-canada-approval-tslim-x2-0
- Brown, S. A., Kovatchev, B. P., Raghinaru, D., et al. (2019). Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. New England Journal of Medicine, 381(18), 1701-1717. https://doi.org/10.1056/NEJMoa1907863
- Breton, M. D., Kovatchev, B. P., Brown, S. A., et al. (2020). One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technology & Therapeutics, 22(10), 709-719. https://doi.org/10.1089/dia.2020.0069
- Tandem Diabetes Care. (2024, December). Tandem t:slim X2 Insulin Pump Now Compatible with Dexcom G7 CGM in Canada. Retrieved from https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-tslim-x2-insulin-pump-now-compatible-dexcom-g7-cgm-canada
- Beck, R. W., Riddlesworth, T., Ruedy, K., et al. (2017). Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA, 317(4), 371-378. https://doi.org/10.1001/jama.2016.19975
- Forlenza, G. P., Carlson, A. L., Gallagher, M. P., et al. (2023). A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with Control-IQ technology in youth and adults from age 2 to 72. Diabetes Technology & Therapeutics, 25(9), 598-607. https://doi.org/10.1089/dia.2023.0123
- Tandem Diabetes Care. (2019, November). Tandem Diabetes Care Announces Health Canada Approval of t:slim X2 Insulin Pump with Basal-IQ Predictive Low-Glucose Suspend Technology. Retrieved from https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-health-canada-approval-tslim-x2
- Connected in Motion. (2020, November). Welcome to Canada: Tandem's Control-IQ receives approval. Retrieved from https://www.connectedinmotion.ca/blog/welcome-to-canada-tandems-control-iq-receives-approval/
- Tandem Diabetes Care. (2024). t:slim X2 Insulin Pump with Control-IQ Technology Product Specifications. Retrieved from https://www.tandemdiabetes.com/products/t-slim-x2-insulin-pump
- Forlenza, G. P., Buckingham, B. A., Brown, S. A., et al. (2018). First outpatient evaluation of a tubeless automated insulin delivery system with customizable glucose targets in children and adults with type 1 diabetes. Diabetes Technology & Therapeutics, 20(6), 385-394. https://doi.org/10.1089/dia.2018.0023
The information in this article is for educational purposes only and should not replace advice from your healthcare provider. Always consult with your diabetes care team before making decisions about diabetes management.
For more information:
- Tandem Diabetes Care Canada: Visit www.tandemdiabetes.ca
- Customer Support: www.tandemdiabetes.ca/support
